Lifesci Capital Upgrades Tarsus Pharmaceuticals (NASDAQ:TARS) to “Strong-Buy”

Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by investment analysts at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS and Q4 2026 earnings at $0.09 EPS.

A number of other research analysts have also commented on TARS. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Barclays began coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, Mizuho started coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Trading Up 1.3%

Tarsus Pharmaceuticals stock opened at $69.79 on Monday. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -43.08 and a beta of 0.55. The firm has a 50-day moving average of $69.79 and a 200-day moving average of $70.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. On average, equities analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. This trade represents a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.97% of the stock is currently owned by company insiders.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Rockefeller Capital Management L.P. increased its position in shares of Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after purchasing an additional 172 shares during the period. State of Wisconsin Investment Board lifted its position in Tarsus Pharmaceuticals by 1.1% during the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after purchasing an additional 332 shares during the period. Federated Hermes Inc. grew its stake in Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after buying an additional 339 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in Tarsus Pharmaceuticals by 11.1% during the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after buying an additional 392 shares in the last quarter. Finally, Creative Planning increased its holdings in Tarsus Pharmaceuticals by 3.3% in the 3rd quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after buying an additional 393 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.